Azafaros A.G.

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

AZ-3102 (Dose 1) · Autoimmune diseases
AZ-3102 is a selective inhibitor of the retinoic acid receptor-related orphan receptor gamma t (RORγt) pathway.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Azafaros A.G. portfolio CI brief
Azafaros A.G. pipeline updates RSS

Frequently asked questions about Azafaros A.G.

What is Azafaros A.G.'s pipeline?

Azafaros A.G. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include AZ-3102 (Dose 1).

Sector hub: All tracked pharma companies